The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation

PLoS Pathogens

Volumn 5, Issue 1, 2009, Pages

  Zuo, Jianmin ^a   Currin, Andrew ^a   Griffin, Bryan D ^b   Shannon Lowe, Claire ^a   Thomas, Wendy A ^a   Ressing, Maaike E ^b   Wiertz, Emmanuel J H J ^c   Rowe, Martin ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LYSOSOMAL PROTEINASE; LYSOSOME ENZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; BILF1 PROTEIN, EPSTEIN BARR VIRUS; BILF1 PROTEIN, EPSTEIN-BARR VIRUS; HLA ANTIGEN CLASS 1; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; BILF1 GENE; CD8+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS; GENE FUNCTION; GENE IDENTIFICATION; GENETIC CODE; HERPES VIRUS; HUMAN; HUMAN CELL; IMMUNOMODULATION; NONHUMAN; PRIMATE; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; VIRUS GENE; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PHYSIOLOGY;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 8; PRIMATES;

CD8-POSITIVE T-LYMPHOCYTES; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; VIRAL PROTEINS;

EID: 59249101973     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000255     Document Type: Article

References (73)

1. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, et al. (2008) Modulation of natural killer cells by human cytomegalovirus. J Clin Virol 41: 206-212.
2. Hengel H, Koopmann JO, Flohr T, Muranyi W, Goulmy E, et al. (1997) A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 6: 623-632.
3. Ahn K, Gruhler A, Galocha B, Jones TR, Wiertz EJ, et al. (1997) The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 6: 613-621.
4. Lehner PJ, Karttunen JT, Wilkinson GW, Cresswell P (1997) The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc Natl Acad Sci USA 94: 6904-6909.
5. Ahn K, Angulo A, Ghazal P, Peterson PA, Yang Y, et al. (1996) Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci USA 93: 10990-10995.
6. Jones TR, Wiertz EJ, Sun L, Fish KN, Nelson JA, et al. (1996) Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci USA 93: 11327-11333.
7. Park B, Kim Y, Shin J, Lee S, Cho K, et al. (2004) Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity 20: 71-85.
8. Furman MH, Dey N, Tortorella D, Ploegh HL (2002) The Human Cytomegalovirus US10 Gene Product Delays Trafficking of Major Histocompatibility Complex Class I Molecules. J Virol 76: 11753-11756.
9. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, et al. (1996) The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84: 769-779.
10. Wiertz EJ, Tortorella D, Bogyo M, Yu J, Mothes W, et al. (1996) Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384: 432-438.
11. Jones TR, Sun L (1997) Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. J Virol 71: 2970-2979.
12. Rickinson AB, Kieff E (2007) Epstein-Barr virus. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Walters Kluwer/Lippincott, Williams & Wilkins. pp 2655-2700.
13. Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. New Engl J Med 350: 1328-1337.
14. Thorley-Lawson DA (2001) Epstein-Barr virus: exploiting the immune system. Nature Rev Immunol 1: 75-82.
15. Hislop AD, Taylor GS, Sauce D, Rickinson AB (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587-617.
16. Gregory CD, Murray RJ, Edwards CF, Rickinson AB (1988) Down regulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumour cell escape from virus-specific T cell surveillance. Journal of Experimental Medicine 167: 1811-1824.
17. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, et al. (1995) Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein Barr Virus Latent Membrane protein-1: Coordinate upregulation of peptide transporters and HLA Class I antigen expression. Eur J Immunol 25: 1374-1384.
18. Purtilo DT (1980) Epstein-Barr-virus-induced oncogenesis in immune-deficient individuals. Lancet 1: 300-303.
19. Keating S, Prince S, Jones M, Rowe M (2002) The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface MHC class I and class II. J Virol 76: 8179-8188.
20. Pudney VA, Leese AM, Rickinson AB, Hislop AD (2005) CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med 201: 349-360.
21. Ressing ME, Keating SE, van Leeuwen D, Koppers-Lalic D, Pappworth IY, et al. (2005) Impaired Transporter Associated with Antigen Processing-dependent peptide transport during productive EBV Infection. J Immunol 174: 6829-6838.
22. Rowe M, Glaunsinger B, van Leeuwen D, Zuo J, Sweetman D, et al. (2007) Host shut off during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci USA 104: 3366-3371.
23. + T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 204: 1863-1873.
24. Zuo J, Thomas W, van Leeuwen D, Middeldorp JM, Wiertz EJ, et al. (2008) The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function. J Virol 82: 2385-2393.
25. Paulsen SJ, Rosenkilde MM, Eugen-Olsen J, Kledal TN (2005) Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. J Virol 79: 536-546.
26. Beisser PS, Verzijl D, Gruijthuijsen YK, Beuken E, Smit MJ, et al. (2005) The Epstein-Barr virus BILF1 gene encodes a G protein-coupled receptor that inhibits phosphorylation of RNA-dependent protein kinase. J Virol 79: 441-449.
27. Rosenkilde MM, Smit MJ, Waldhoer M (2008) Structure, function and physiological consequences of virally encoded chemokine seven transmembrane receptors. Br J Pharmacol 153 Suppl 1: S154-166.
28. Reusch U, Muranyi W, Lucin P, Burgert HG, Hengel H, et al. (1999) A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation. EMBO J 18: 1081-1091.
29. Coscoy L, Ganem D (2000) Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc Natl Acad Sci USA 97: 8051-8056.
30. Drose S, Altendorf K (1997) Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases. J Exp Biol 200: 1-8.
31. Clague MJ, Urbe S, Aniento F, Gruenberg J (1994) Vacuolar ATPase activity is required for endosomal carrier vesicle formation. J Biol Chem 269: 21-24.
32. Grinde B, Seglen PO (1980) Differential effects of proteinase inhibitors and amines on the lysosomal and non-lysosomal pathways of protein degradation in isolated rat hepatocytes. Biochim Biophys Acta 632: 73-86.
33. Lee DH, Goldberg AL (1998) Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 8: 397-403.
34. Wess J (1998) Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol Ther 80: 231-264.
35. Fogg MH, Kaur A, Cho YG, Wang F (2005) The CD8+ T-Cell Response to an Epstein-Barr Virus-Related Gammaherpesvirus Infecting Rhesus Macaques Provides Evidence for Immune Evasion by the EBNA-1 Homologue. J Virol 79: 12681-12691.
36. Wang F, Rivailler P, Rao P, Cho Y (2001) Simian homologues of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 356: 489-497.
37. Yuan J, Cahir-McFarland E, Zhao B, Kieff E (2006) Virus and cell RNAs expressed during Epstein-Barr virus replication. J Virol 80: 2548-2565.
38. Zeidler R, Eissner G, Meissner P, Uebel S, Tampe R, et al. (1997) Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 90: 2390-2397.
39. Guo HG, Sadowska M, Reid W, Tschachler E, Hayward G, et al. (2003) Kaposi's sarcoma-like tumors in a human herpesvirus 8 ORF74 transgenic mouse. J Virol 77: 2631-2639.
40. Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, et al. (2003) Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3: 23-36.
41. Yang TY, Chen SC, Leach MW, Manfra D, Homey B, et al. (2000) Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 191: 445-454.
42. Stern JL, Slobedman B (2008) Human cytomegalovirus latent infection of myeloid cells directs monocyte migration by up-regulating monocyte chemotactic protein-1. J Immunol 180: 6577-6585.
43. Hirsch AJ, Shenk T (1999) Human cytomegalovirus inhibits transcription of the CC chemokine MCP-1 gene. J Virol 73: 404-410.
44. Milne RS, Mattick C, Nicholson L, Devaraj P, Alcami A, et al. (2000) RANTES binding and down-regulation by a novel human herpesvirus-6 beta chemokine receptor. J Immunol 164: 2396-2404.
45. Wang Z, Zhang L, Qiao A, Watson K, Zhang J, et al. (2008) Activation of CXCR4 triggers ubiquitination and down-regulation of major histocompatibility complex class I (MHC-I) on epithelioid carcinoma HeLa cells. J Biol Chem 283: 3951-3959.
46. Stevenson PG, Efstathiou S, Doherty PC, Lehner PJ (2000) Inhibition of MHC class I-restricted antigen presentation by gamma 2-herpesviruses. Proc Natl Acad Sci USA 97: 8455-8460.
47. Ishido S, Wang C, Lee BS, Cohen GB, Jung JU (2000) Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol 74: 5300-5309.
48. Coscoy L, Sanchez DJ, Ganem D (2001) A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition. J Cell Biol 155: 1265-1273.
49. Hewitt EW, Duncan L, Mufti D, Baker J, Stevenson PG, et al. (2002) Ubiquitylation of MHC class I by the K3 viral protein signals internalization and TSG101-dependent degradation. EMBO J 21: 2418-2429.
50. Aasland R, Gibson TJ, Stewart AF (1995) The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem Sci 20: 56-59.
51. Joazeiro CA, Weissman AM (2000) RING finger proteins: mediators of ubiquitin ligase activity. Cell 102: 549-552.
52. Glosson NL, Hudson AW (2007) Human herpesvirus-6A and -6B encode viral immunoevasins that downregulate class I MHC molecules. Virology 365: 125-135.
53. Chaudhuri R, Lindwasser OW, Smith WJ, Hurley JH, Bonifacino JS (2007) Downregulation of CD4 by human immunodeficiency virus type 1 Nef is dependent on clathrin and involves direct interaction of Nef with the AP2 clathrin adaptor. J Virol 81: 3877-3890.
54. Janvier K, Kato Y, Boehm M, Rose JR, Martina JA, et al. (2003) Recognition of dileucine-based sorting signals from HIV-1 Nef and LIMP-II by the AP-1 gamma-sigma1 and AP-3 delta-sigma3 hemicomplexes. J Cell Biol 163: 1281-1290.
55. Greenberg M, DeTulleo L, Rapoport I, Skowronski J, Kirchhausen T (1998) A dileucine motif in HIV-1 Nef is essential for sorting into clathrin-coated pits and for downregulation of CD4. Curr Biol 8: 1239-1242.
56. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM (1996) Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 2: 338-342.
57. Kasper MR, Collins KL (2003) Nef-mediated disruption of HLA-A2 transport to the cell surface in T cells. J Virol 77: 3041-3049.
58. Le Gall S, Buseyne F, Trocha A, Walker BD, Heard JM, et al. (2000) Distinct trafficking pathways mediate Nef-induced and clathrin-dependent major histocompatibility complex class I down-regulation. J Virol 74: 9256-9266.
59. Lubben NB, Sahlender DA, Motley AM, Lehner PJ, Benaroch P, et al. (2007) HIV-1 Nef-induced down-regulation of MHC class I requires AP-1 and clathrin but not PACS-1 and is impeded by AP-2. Mol Biol Cell 18: 3351-3365.
60. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W (1998) Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci USA 95: 8245-8250.
61. Zhou FC, Zhang YJ, Deng JH, Wang XP, Pan HY, et al. (2002) Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J Virol 76: 6185-6196.
62. Rivailler P, Jiang H, Cho YG, Quink C, Wang F (2002) Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-Barr virus animal model. J Virol 76: 421-426.
63. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, et al. (2001) Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 98: 9237-9242.
64. Johnson JP, Demmer-Dieckmann M, Meo T, Hadam MR, Riethmuller G (1981) Surface antigens of human melanoma cells defined by monoclonal antibodies. I. Biochemical characterization of two antigens found on cell lines and fresh tumors of diverse tissue origin. Eur J Immunol 11: 825-831.
65. Rabin H, Hopkins RF 3rd, Ruscetti FW, Neubauer RH, Brown RL, et al. (1981) Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells. J Immunol 127: 1852-1856.
66. Young LS, Lau R, Rowe M, Niedobitek G, Packham G, et al. (1991) Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral "hairy" leukoplakia. J Virol 65: 2868-2874.
67. Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, et al. (1978) Production of a monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 14: 9-20.
68. Stam NJ, Spits H, Ploegh HL (1986) Monoclonal-antibodies raised against denatured HLA-B locus heavy-chains permit biochemical-characterization of certain HLA-C locus products. J Immunol 137: 2299-2306.
69. Lampson LA, Levy R (1980) Two populations of Ia-like molecules on a human B cell line. J Immunol 125: 293-299.
70. Meyer TH, van Endert PM, Uebel S, Ehring B, Tampe R (1994) Functional expression and purification of the ABC transporter complex associated with antigen processing (TAP) in insect cells. FEBS Letts 351: 443-447.
71. Long HM, Haigh TA, Gudgeon NH, Leen AM, Tsang CW, et al. (2005) CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol 79: 4896-4907.
72. Lee SP, Brooks JM, Al-Jarrah H, Thomas WA, Haigh TA, et al. (2004) CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J Exp Med 199: 1409-1420.
73. Lee SP, Thomas WA, Murray RJ, Khanim F, Kaur S, et al. (1993) HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 67: 7428-7435.